An observational study in Burn Injuries, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Ain Shams University · Observational
The aim of this study is to evaluate the prognostic utility of the red cell distribution width/albumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.
The aim of this study is to evaluate the prognostic utility of the red cell distribution width/albumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.
Patients presenting with acute thermal injuries will be screened based on inclusion/exclusion criteria.
After consent, patients' characteristics (age, sex, weight), clinical parameters (total burn surface area, Abbreviated Burn Severity Index), and comorbidities will be recorded.
Emergency Department (ED) management (Arrival and Initial Stabilization)
In-Hospital Resuscitation (0-72 h)
Laboratory and calculation:
On admission to ED, an arterial blood gas (ABG) sample will be collected to calculate base deficit (BD) and lactate level.
Simultaneously, venous blood will be drawn for C-reactive protein (CRP) and serum albumin, CBC, serum urea, creatinine, AST, ALT, and electrolytes (Na+, K+, Mg+) estimation.
Red Cell Distribution Width/Albumin will be calculated as:
((RDW (Standard Deviation of Red Blood Cell Volume / Mean Corpuscular Volume) × 100%.) / albumin (g/L)) from admission labs.
Serial: Lactate/Base Deficit at 6 hr, 12 hr, 24 hr as a monitor for proper resuscitation Calculation of Severity Scores
Both scores will be calculated on admission and compared with admission (RDW/albumin) ratio to assess relative and incremental predictive value for 30-day mortality.
Supportive care:
Vasopressors (norepinephrine) only after adequate fluid resuscitation guided by UOP, lactate and BD if MAP below 65 mmHg.
3 - Post-Resuscitation and Definitive Management Protocol (After 72 h) Hemodynamic stabilization (post-resuscitation phase) Transition from resuscitation fluids to maintenance fluids. Avoid "fluid creep" (excess positive balance leading to pulmonary edema, abdominal compartment). → cautious use of diuretics to mobilize edema.
Maintain: MAP ≥65 mmHg, urine output ≥0.5 mL/kg/h. Ongoing ventilatory support if required; lung-protective strategy for ARDS. Weaning as early as possible.
Infection prevention and sepsis monitoring
Wound care and surgical management
Rehabilitation and functional recovery • Early physiotherapy, occupational therapy for daily living skills and psychosocial support for patient and family.
Criteria for transfer to ward • Hemodynamically stable, off vasopressors.
Primary outcome:
To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30-day hospital mortality in burn patients.
Secondary outcomes:
To determine the correlation between Red Cell Distribution Width/Albumin with:
905 studies on the registry are indexed under Burns; 164 are open to participants now.
This study's planned enrollment of 30 is below the median of 64 across 163 observational studies indexed under Burns.
Browse Burns studies →Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients presenting with acute thermal injuries will be screened based on inclusion/exclusion criteria.
After consent, Patients' characteristics (age, sex, weight), clinical parameters (Total burn surface area, Abbreviated burn severity index), and comorbidities will be recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
each patient will be followed for 30 days for mortality prediction
mortality in burn patients
To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30 days hospital mortality in burn patients.
Time frame: 30 days
ICU length of stay
To determine the correlation between Red Cell Distribution Width/Albumin with o ICU length of stay
Time frame: 30 days
To compare RDW/albumin ratio with Revised Baux score as a predictor of mortality in burn patient.
Revised Baux score = (percent body surface burned) + (patient's age) + 17 (if inhalational injury is present) A higher Revised Baux score generally indicates a higher risk of mortality, with scores over 140 unsurvivable .
Time frame: 30 days
Requirements of inotropes or vasopressors
To determine the correlation between Red Cell Distribution Width/Albumin with o Requirements of inotropes or vasopressors
Time frame: 30 days
Duration of mechanical ventilation
To determine the correlation between Red Cell Distribution Width/Albumin with o Duration of mechanical ventilation
Time frame: 30 days
Plan to share: Yes — De-identified individual participant data underlying the study results will be made available upon reasonable request from qualified researchers
Supporting information: Study protocol
Time frame: Within 6:12 months
Access criteria: Access will be granted to researchers who submit a methodologically sound proposal to the principal investigator. Requests should be directed to g19-29502090100101@med.asu.edu.eg
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.
Of 56 non-industry observational studies under Burns, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's planned 6 months is below that.
Counting every sponsor, half of 68 studies reached it within 24 months; a quarter within 14 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.